Vakona is developing a groundbreaking skin product for acneic skin. Several factors contribute to acne, with an imbalance in the skin’s microbiome being a key issue. The overgrowth of Cutibacterium acnes and its ability to form biofilms are central to acne lesion formation and can lead to treatment failures with antibiotics. Vakona’s product, designed as a cream/gel, features a naturally occurring bacterial enzyme that breaks down the biofilm created by Cutibacterium acnes. Unlike other acne treatments that target the bacteria directly, this formula does not have a direct anti-bacterial effect, making the skin microbiome intact. This innovative approach introduces a new mechanism of action, potentially delivering faster results without the side effects commonly seen with traditional acne products.

Vakona AB

Org chart

Teams

Offices